Zentalis Pharmaceuticals Inc. (ZNTL) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Zentalis Pharmaceuticals ...

    NASDAQ: ZNTL · Real-Time Price · USD
    1.77
    0.00 (0.00%)
    At close: Sep 05, 2025, 11:38 AM

    Zentalis Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 67.42M n/a n/a n/a
    Cost of Revenue
    		 1.29M 1.39M 1.43M 544K
    Gross Profit
    		 67.42M -1.39M -1.43M -544K
    Operating Income
    		 -191.19M -253.94M -227.29M -216.54M
    Interest Income
    		 n/a n/a 2.26K 1.31K
    Pretax Income
    		 -165.69M -292.91M -221.3M -164.56M
    Net Income
    		 -165.84M -292.19M -236.81M -158.72M
    Selling & General & Admin
    		 87.11M 59.4M 54.55M 40.94M
    Research & Development
    		 167.77M 189.59M 172.73M 175.6M
    Other Expenses
    		 3.74M 3.56M n/a n/a
    Operating Expenses
    		 258.62M 252.55M 227.29M 216.54M
    Interest Expense
    		 n/a n/a 2.58M n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 258.62M 253.94M 227.29M 216.54M
    Income Tax Expense
    		 177K -601K -469K -297K
    Shares Outstanding (Basic)
    		 71.08M 65.41M 52.86M 42.69M
    Shares Outstanding (Diluted)
    		 71.08M 65.41M 52.86M 42.69M
    EPS (Basic)
    		 -2.33 -4.47 -4.48 -3.72
    EPS (Diluted)
    		 -2.33 -4.47 -4.48 -3.72
    EBITDA
    		 -186.17M -275.5M -219.87M -164.01M
    EBIT
    		 -187.46M -276.89M -221.3M -164.56M
    Depreciation & Amortization
    		 1.29M 1.39M 1.43M 544K

    Add to Watchlist